Background: Chronic kidney disease (CKD) is common, but the longitudinal effects of CKD and associated comorbidities on health care costs in the general population are unknown. Methods: Population-based cohort study of 2,988 subjects in Germany, aged 25–74 years at baseline, who participated both in the baseline and 10-year follow-up examination (1994/95–2004/05). Presence of CKD was based on serum creatinine and defined as an estimated glomerular filtration rate of <60 ml/min/1.73 m2. Self-reported health services utilization was used to estimate costs. Results: Health care costs at baseline and follow-up were higher for subjects with CKD. Controlling for socio-economics, lifestyle factors and comorbid conditions, subjects with baseline CKD, in comparison to those without, exhibited 65% higher total costs 10 years after baseline examination, corresponding to a difference in adjusted costs of EUR 743. Incident CKD was related to 38% higher total costs. Costs for inpatient treatment and drug costs were the major costs components, while CKD revealed no effect on outpatient costs. The effect of CKD was strongly modified by angina, myocardial infarction, diabetes, and anemia. Conclusions: The direct effect of CKD on costs is modified by comorbid conditions. Therefore, early treatment of CKD and its precipitous factors may save future health care costs.

1.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the united states. JAMA 2007;298:2038–2047.
2.
Glassock RJ, Winearls C: The global burden of chronic kidney disease: How valid are the estimates? Nephron Clin Pract 2008;110:c39–c47.
3.
Meguid El Nahas A, Bello AK: Chronic kidney disease: the global challenge. Lancet 2005;365:331–340.
4.
Khan S, Amedia CA Jr: Economic burden of chronic kidney disease. J Eval Clin Pract 2008;14:422–434.
5.
Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85–97.
6.
Alexander M, Bradbury BD, Kewalramani R, Barlev A, Mohanty SA, Globe D: Chronic kidney disease and US healthcare resource utilization in a nationally representative sample. Am J Nephrol 2009;29:473–482.
7.
Smith DH, Nichols G, Gullion CM, Johnson ES, Keith DS: Predicting costs of care in chronic kidney disease: the role of comorbid conditions. The Internet Journal of Nephrology 2007;4.
8.
Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB: Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004;15:1300–1306.
9.
Brown JB, Pedula KL, Bakst AW: The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873–1880.
10.
Meyer A, Bunzemeier H, Hausberg M, Walter M, Roeder N, Breithardt G, Reinecke H: Impact of different stages of chronic kidney disease on in-hospital costs in patients with coronary heart disease. Nephrol Dial Transplant 2008;23:1955–1960.
11.
Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT: Health care utilization among patients with chronic kidney disease. Kidney Int 2002;62:229–236.
12.
Keil U, Liese AD, Hense HW, Filipiak B, Doring A, Stieber J, Lowel H: Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany: results from the MONICA Augsburg cohort study 1984–1992. Monitoring trends and determinants in cardiovascular diseases. Eur Heart J 1998;19:1197–1207.
13.
Evans A, Tolonen H, Hense HW, Ferrario M, Sans S, Kuulasmaa K: Trends in coronary risk factors in the who MONICA project. Int J Epidemiol 2001;30(suppl 1):S35–S40.
14.
Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.
15.
Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C, Group tHC: German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health, in press.
16.
Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B: Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation – ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation. Gesundheitswesen 2005;67:736–746.
17.
German Hospital Federation: A survey of hospital planning and investment financing in the German federal states (www.dkgev.de), 2006.
18.
Rote Liste Service GmbH: Arzneimittelverzeichnis für Deutschland. Frankfurt am Main, ECV Editio Cantor Verlag, 2004.
19.
Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F: Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766–772.
20.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
21.
Luepker RV, Evans A, McKeigue P, Reddy KS: Cardiovascular survey methods. Geneva, WHO, 2004.
22.
Kawachi I, Kennedy BP: The relationship of income inequality to mortality: does the choice of indicator matter? Soc Sci Med 1997;45:1121–1127.
23.
Doring A, Filipiak B, Stieber J, Keil U: Trends in alcohol intake in a southern german population from 1984–1985 to 1989–1990: results of the MONICA project Augsburg. J Stud Alcohol 1993;54:745–749.
24.
Manning WG, Basu A, Mullahy J: Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005;24:465–488.
25.
Carlin JB, Wolfe R, Coffey C, Patton GC: Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete-time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat Med 1999;18:2655–2679.
26.
Tian L, Huang J: A two-part model for censored medical cost data. Stat Med 2007;26:4273–4292.
27.
Localio AR, Margolis DJ, Berlin JA: Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol 2007;60:874–882.
28.
St Peter WL, Khan SS, Ebben JP, Pereira BJ, Collins AJ: Chronic kidney disease: the distribution of health care dollars. Kidney Int 2004;66:313–321.
29.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034–2047.
30.
Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, Burns K, Manns B, White C, Madore F, Moist L, Klarenbach S, Barrett B, Foley R, Jindal K, Senior P, Pannu N, Shurraw S, Akbari A, Cohn A, Reslerova M, Deved V, Mendelssohn D, Nesrallah G, Kappel J, Tonelli M: Guidelines for the management of chronic kidney disease. CMAJ 2008;179:1154–1162.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.